Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital

Core Viewpoint - Altimmune, Inc. has secured a credit facility of up to $100 million from Hercules Capital to support the development of its novel peptide-based therapeutic, pemvidutide, aimed at treating liver and cardiometabolic diseases [1][2]. Financial Strength and Flexibility - The credit facility enhances Altimmune's balance sheet, which had $150 million in cash and cash equivalents as of March 31, 2025 [2]. - The initial tranche of $15 million will be drawn at closing, with additional funds available upon meeting specific clinical and financial milestones [3]. Development Plans for Pemvidutide - Pemvidutide is currently in a Phase 2b trial for metabolic dysfunction-associated steatohepatitis (MASH), with top-line data expected in Q2 2025 [2]. - Phase 2 trials for pemvidutide in Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD) are anticipated to start in the second and third quarters of 2025, respectively [2]. Partnership and Future Outlook - The partnership with Hercules Capital is expected to extend Altimmune's cash runway under flexible terms, allowing for continued development of pemvidutide [3]. - Hercules Capital expresses enthusiasm in supporting Altimmune through its clinical development journey, particularly with the upcoming data release from the IMPACT trial [3]. Company Overview - Altimmune is a late clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for liver and cardiometabolic diseases, with pemvidutide as its lead program [4].